CXCR3 and metabolic dysfunction-associated steatotic liver disease: The application of 2‐DG or the deletion of cell‐specific PKM2 can diminish the presence of specific CXCR3+ Th17 (ihTh17) cells in nonalcoholic fatty liver disease (NAFLD), ultimately mitigating the NAFLD driven by Th17 cells.94